Plot of major adverse events after 208 percutaneous cryoablation sessions of 310 lung tumors in 139 patients—versus session’s hospital length of stay

Plot of major adverse events after 208 percutaneous cryoablation sessions of 310 lung tumors in 139 patients—versus session’s hospital length of stay. Each circle represents one event. Shading of circle represents ventilation modality. Size of circle represents CTCAE grade. Major adverse events were defined as CTCAE grade ≥ 3. CTCAE, Common Terminology Criteria for Adverse Events. One grade 4 pneumothorax resulted in intraprocedural cardiac arrest due to impeded venous return. 

 


January 25, 2024 — According to the American Journal of Roentgenology (AJR), high-frequency jet ventilation appears to be as safe as spontaneous respiration (SR) for percutaneous lung ablation and could increase procedural efficiency, especially for complex cases. 

“HFJV appears to be as safe as SR but had longer room times,” clarified corresponding author and 2019 ARRS Scholar Florian J. Fintelmann, MD, from Massachusetts General Hospital in Boston. “HFJV can be used in complex cases without significantly impacting hospital length of stay (HLOS) longer than or equal to 2 days, procedure time, or radiation exposure.” 

This AJR accepted manuscript included consecutive adults who underwent CT-guided percutaneous cryoablation of one or more lung tumors with HFJV or SR (January 1, 2017–May 31, 2023). Fintelmann et al. compared major (grade ≥ 3) Common Terminology Criteria for Adverse Events (CTCAE) within 30 days and HLOS ≥ 2 days. Using generalized estimating equations, the AJR authors then compared procedure, room, and CT guidance acquisition times, CT guidance radiation and total radiation dosage, as well as pneumothorax. 

Ultimately, for 208 cryoablations of 310 lung tumors in 139 patients, HFJV—compared with SR—was more commonly used to treat multiple tumors per session (43% vs. 19%; p =.02) and non-peripheral tumors (48% vs. 24%; p <.001), without significant differences in major adverse event rates, procedure times, or radiation exposure (p > .05). 

“The choice of ventilation modality during percutaneous lung ablation should be based on patient characteristics and anticipated procedural requirements, as well as operator preference,” Fintelmann et al. added

For more information: www.arrs.org


Related Content

News | Lung Imaging

April, 15, 2025 — Optellum has entered an agreement with Bristol Myers Squibb to leverage AI in early diagnosis and ...

Time April 17, 2025
arrow
News | Pediatric Imaging

April 10, 2025 — Cincinnati Children’s and GE HealthCare will form a strategic research program focused on driving ...

Time April 10, 2025
arrow
News | SPECT Imaging

Feb. 5, 2025 — Serac Healthcare Ltd., a clinical radiopharmaceutical company developing an innovative molecular imaging ...

Time February 05, 2025
arrow
News | Computed Tomography (CT)

Dec. 3, 2024 — During RSNA '24, GE HealthCare announced the 510(k) submission to the U.S. Food and Drug Administration ...

Time December 18, 2024
arrow
News | SPECT Imaging

Dec. 2, 2024 — GE HealthCare has agreed to acquire full ownership of Nihon Medi-Physics Co., Ltd (NMP), by purchasing ...

Time December 05, 2024
arrow
News | Artificial Intelligence

Sept. 13, 2024 — Bayer Calantic Digital Solutions has announced the availability of a new eBook that addresses how ...

Time September 12, 2024
arrow
News | Computed Tomography (CT)

At the annual AHRA (American Healthcare Radiology Administrators) conference in Orlando, Florida, Bayer announced an ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Videos | Radiology Business

Find actionable insights to achieve sustainability and savings in radiology in this newest of ITN’s “One on One” video ...

Time July 30, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
Subscribe Now